FDA Brief

Warning letters Food

FDA warning letter to

Jackson Health & Wellness Clinic

LowIssued Feb 3, 2023Posted Feb 28, 2023Division of Human and Animal Food Operations East V

FDA warned Jackson Health & Wellness Clinic that website claims for Dr. Miller’s teas and supplements make them unapproved and misbranded drugs.

What happened

FDA reviewed the clinic’s websites in October 2022 and January 2023 and found orders for Dr. Miller’s Holy Tea, Super Holy Tea, Ultimate Tea, Be Free Spring Clean Herbal Detox, and Youthin Fatburners. The sites claimed these products could treat or relieve diseases including acid reflux, IBS, Crohn’s disease, high blood pressure, high cholesterol, parasites, viruses, and bacteria. FDA said the claims and testimonials establish the products are drugs, but they are not FDA-approved and lack adequate directions for use.

What FDA found

  1. The websites claim the teas and supplements cure, treat, or prevent diseases, so FDA treats them as drugs.

    section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. § 321(g)(1)(B)]
  2. The products are new drugs because they are not generally recognized as safe and effective for these uses and lack FDA approval.

    sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The products are misbranded because they do not have adequate directions for a layperson to use them safely for the claimed diseases.

    section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Some claimed uses are for diseases that cannot be safely self-diagnosed or self-treated without a licensed practitioner, so adequate directions cannot be written.

    section 502(f)(1) [21 U.S.C. 352(f)(1)]
  5. Website testimonials describing migraine, Crohn’s disease, IBS, and acid reflux relief also show the products are intended as drugs.

    section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the letter about specific steps taken to address the violations, including steps to prevent recurrence and related documentation. If corrective actions cannot be completed within 15 working days, the company must state the reason for delay and the time within which it will do so.

Who should pay attention

  • clinics and practitioners selling own-brand supplements
  • dietary supplement brands making disease-treatment claims
  • companies that publish customer testimonials as product evidence

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk